CD274 and neoplasm: In patients with advanced HPV-positive squamous cell cancers of the head/neck and of the cervix, MEDI0457 was safe/well-tolerated and associated with an increased anti-HPV-16/HPV-18 B-cell and T-cell immunity against the E6 and E7 targets.18,19 Here, we evaluated the anti-tumor activity and toxicity profile of the combination of MEDI0457 and the anti-PD-L1 antibody durvalumab for patients with recurrent or metastatic HPV-associated anogenital cancers.